IL33 and graft versus host disease: Many recent findings strongly suggest a functional role of the IL33/ST2 axis in the modulation of aGVHD in preclinical studies, while high levels of sST2 and IL-33 in the serum have been suggested as a marker for the risk of therapy-resistant GVHD and death [31,33].